Unlike THC, CBD will not make you high. That said, this doesn’t mean CBD is not at all psychoactive, as many assert, says Jahan Marcu, PhD, director of experimental pharmacology and behavior at the International Research Center on Cannabis and Mental Health in New York City: “CBD does change cognition. It affects mood, which is why people take it for anxiety. And some find that it makes them more alert.”
Other targets for CBD include transient receptor potential (TRP) channels that are involved with the modulation of intracellular calcium (1, 6). Cannabinoids are highly lipophilic, allowing access to intracellular sites of action, resulting in increases in calcium in a variety of cell types including hippocampal neurons. CBD actions on calcium homeostasis may provide a basis for CBD neuroprotective properties.
Hemp oil does have a number of uses and is often marketed as a cooking oil or a product that is good for moisturizing the skin. It is also used in the production of certain soaps, shampoos, and foods. It is also a basic ingredient for bio-fuel and even a more sustainable form of plastic. Hemp has been cultivated and used for roughly 10,000 years, and it definitely has useful purposes. However, a lack of cannabinoids, namely CBD, means that it has little therapeutic value.
But scientists have found that CBD doesn’t bind well with endocannabinoid receptors. Instead, CBD influences the system indirectly. This creates many benefits, which is why you’ll hear of CBD as a treatment for so many different medical conditions. And, unlike THC, it won’t make you high. When it comes to pain, we know that CBD has multiple functions. First, it influences neurotransmitters and receptors. One receptor known to be involved with pain and inflammation is called TRPV1 — also known as a vanilloid receptor. CBD binds to the TRPV1 receptor, influencing the way you perceive pain. CBD can also affect the production of neurotransmitters like serotonin and glutamate, which are related to pain sensation.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
This is why Amanda Oliver, 31, a career consultant in Charleston, SC, pops a CBD gummy bear each night before bed. “I used to lie there tossing and turning as my mind raced from work projects to whether I had set the home alarm,” Oliver says. One piece of candy with 15 milligrams (mg) of CBD is enough to shut off her brain and facilitate sleep. She also swears by the CBD oil she takes at the height of her period, which she says quells her debilitating cramps.